Gene Therapy webinar series – Episode 4: N-of-1 to many personalized therapies

14 May 2024



Click here to register!

…TIMESLOT: Tuesday 14 May – 16:00 – 17:00 CEST

…THEME: N-of-1 to many personalized therapies

…PRESENTERS: Terry Pirovolakis, Founder of CureSPG50 and Elpida Therapeutics

Terry Pirovolakis, co-founder of CureSPG50, confronted his child’s SPG50 diagnosis in 2019. Through successful fundraising, he led ground-breaking research, treating three children within three years. Pirovolakis established Elpida Therapeutics, a corporation with a non-profit approach, focusing on gene therapies for ultra-rare conditions. Collaborating with industry leaders, Elpida targets SPG50, CMT4J, and plans to address three more diseases in 2024, utilizing profits to sustain programs. Pirovolakis extends his impact by supporting foundations, providing Gene Therapy 101 classes, and engaging in collaborations, all centered on the goal of saving as many children as possible. 

Fore more information on the full Gene Therapy webinar series click here!

Further details

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit